{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:30:33Z","timestamp":1792290633998,"version":"4.4.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Defense against<jats:italic>Haemophilus influenzae<\/jats:italic>type b (Hib) is dependent on antibodies and complement, which mediate both serum bactericidal activity (SBA) and opsonophagocytosis. Here we evaluated the influence of capsule-specific antibodies and complement inhibitors targeting the central component C3, the alternative pathway (AP; fB, fD), the lectin pathway (LP; MASP-2) and the terminal pathway (C5) on both effector functions. Findings may be relevant for the treatment of certain diseases caused by dysregulation of the complement system, where inhibitors of complement factors C3 or C5 are used. Inhibitors against other complement components are being evaluated as potential alternative treatment options that may carry a reduced risk of infection by encapsulated bacteria. Serum and reconstituted blood of healthy adults were tested for bactericidal activity before and after vaccination with the Hib capsule-conjugate vaccine ActHIB. Most sera had bactericidal activity prior to vaccination, but vaccination significantly enhanced SBA titers. Independently of the vaccination status, both C3 and C5 inhibition abrogated SBA, whereas inhibition of the LP had no effect. AP inhibition had a major inhibitory effect on SBA of pre- vaccination serum, but vaccination mitigated this inhibition for all disease isolates tested. Despite this, SBA-mediated killing of some Hib isolates remained retarded. Even for the most serum-resistant isolate, SBA was the dominating defense mechanism in reconstituted whole blood, as addition of blood cells to the serum did not enhance bacterial killing. Limited Fc receptor-mediated opsonophagocytosis was unmasked when bacterial killing by the membrane attack complex was blocked. In the presence of C3 or C5 inhibitors, addition of post-vaccination, but not of pre-vaccination serum to the blood cells triggered opsonophagocytosis, leading to suppression of bacterial multiplication. Taken together, our data indicate that for host defense against Hib, killing by SBA is more efficient than by blood cell opsonophagocytosis. However, additional defense mechanisms, such as bacterial clearance by spleen and liver, may play an important role in preventing Hib-mediated sepsis, in particular for Hib isolates with increased serum-resistance. Results indicate potentially improved safety profile of AP inhibitors over C3 and C5 inhibitors as alternative therapeutic agents in patients with increased susceptibility to Hib infection.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1020580","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T10:50:51Z","timestamp":1670842251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b"],"prefix":"10.3389","volume":"13","author":[{"given":"Lukas","family":"Muri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Thorburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Zamurovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Holbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kamm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Pluschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ispasanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of streptococcus pneumoniae and haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Heal"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05476-11","article-title":"Haemophilus influenzae infections in the h","volume":"49","author":"Agrawal","year":"2011","journal-title":"influenzae type b conjugate Vaccine era J Clin Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01971.x","article-title":"Haemophilus influenzae type b conjugate vaccines","volume":"113","author":"Kelly","year":"2004","journal-title":"Immunology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.2.356","article-title":"Genes involved in haemophilus influenzae type b capsule expression are frequently amplified","volume":"167","author":"Hoiseth","year":"1993","journal-title":"J Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.4.1106","article-title":"Genes involved in haemophilus influenzae type b capsule expression are part of an 18-kilobase tandem duplication","volume":"83","author":"Hoiseth","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.03.016","article-title":"Community-acquired haemophilus influenzae meningitis in adults","volume":"82","author":"Chekrouni","year":"2021","journal-title":"J Infect"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66788-8","article-title":"Elimination of haemophilus influenzae type b (Hib) disease from the Gambia after the introduction of routine immunisation with a hib conjugate vaccine: a prospective study","volume":"366","author":"Adegbola","year":"2005","journal-title":"Lancet (London England)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jama.1993.03500020080036","article-title":"Declining incidence of haemophilus influenzae type b disease since introduction of vaccination","volume":"269","author":"Murphy","year":"1993","journal-title":"JAMA J Am Med Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(15)00316-2","article-title":"Effect of haemophilus influenzae type b vaccination without a booster dose on invasive h influenzae type b disease, nasopharyngeal carriage, and population immunity in kilifi, Kenya: a 15-year regional surveillance study","volume":"4","author":"Hammitt","year":"2016","journal-title":"Lancet Glob Heal"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61187-8","article-title":"Effect of vaccines on bacterial meningitis worldwide","volume":"380","author":"McIntyre","year":"2012","journal-title":"Lancet (London England)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"16074","DOI":"10.1038\/nrdp.2016.74","article-title":"Community-acquired bacterial meningitis","volume":"2","author":"van de Beek","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.010","article-title":"Evaluation and validation of a serum bactericidal antibody assay for haemophilus influenzae type b and the threshold of protection","volume":"32","author":"Townsend","year":"2014","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.24.4.273","article-title":"Influenzal meningitis","volume":"24","author":"Fothergill","year":"1933","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/infdis\/153.1.8","article-title":"Functional characterization of human IgG, IgM, and IgA antibody directed to the capsule of haemophilus influenzae type b","volume":"153","author":"Schreiber","year":"1986","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0882-4010(91)90010-8","article-title":"Complement-mediated serum activities against genetically defined capsular transformants of haemophilus influenzae","volume":"10","author":"Swift","year":"1991","journal-title":"Microb Pathog"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.04.029","article-title":"Complement in human diseases: Lessons from complement deficiencies","volume":"46","author":"Botto","year":"2009","journal-title":"Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.133","article-title":"Links between complement abnormalities and systemic lupus erythematosus","volume":"39","author":"Pickering","year":"2000","journal-title":"Rheumatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2006.01729.x","article-title":"Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor h","volume":"63","author":"Reis E","year":"2006","journal-title":"Scand J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1987.tb10514.x","article-title":"C2 deficiency, moderately low IgG2 concentrations and lack of the G2m(23) allotype marker in a child with repeated bacterial infections","volume":"76","author":"Sj\u00f6holm","year":"1987","journal-title":"Acta Paediatr Scand"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.1.248","article-title":"C4B deficiency: a risk factor for bacteremia with encapsulated organisms","volume":"162","author":"Bishof","year":"1990","journal-title":"J Infect Dis"},{"key":"B22","article-title":"Functional deficiency of complement factor d in a monozygous twin","volume":"58","author":"Kluin-Nelemans","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165-Supplement_1-S62","article-title":"The role of complement in the host\u2019s defense against haemophilus influenzae","author":"Winkelstein","year":"1992","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1128\/iai.60.1.19-24.1992","article-title":"Complement component 3 binding to haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies","volume":"60","author":"Hetherington","year":"1992","journal-title":"Infect Immun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2106424","article-title":"Pegcetacoplan versus eculizumab in PNH","volume":"385","author":"Ueda","year":"2021","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.1900031","article-title":"Effect of a C1s inhibitor on the efficacy of anti-capsular antibodies against neisseria meningitidis and streptococcus pneumoniae","volume":"3","author":"Lewis","year":"2019","journal-title":"ImmunoHorizons"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab safety: Five-year experience from the global atypical hemolytic uremic syndrome registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732146","article-title":"Alternative complement pathway inhibition abrogates pneumococcal opsonophagocytosis in vaccine-na\u00efve, but not in vaccinated individuals","volume":"12","author":"Muri","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.747594","article-title":"Alternative complement pathway inhibition does not abrogate meningococcal killing by serum of vaccinated individuals","volume":"12","author":"Ispasanie","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy609","article-title":"A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor h binding protein elicits gonococcal bactericidal antibodies","volume":"219","author":"Beernink","year":"2019","journal-title":"J Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. i. the role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup c conjugate vaccines in the united kingdom: Reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor b inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","first-page":"3433","article-title":"Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration | IOVS | ARVO journals","volume":"55","author":"Roguska","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202007-2778LE","article-title":"Complement inhibition with the C5 blocker LFG316 in severe COVID-19","volume":"202","author":"Zelek","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cei.13497","article-title":"MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab","volume":"203","author":"Elhadad","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of haemophilus influenzae type b","volume":"147","author":"Kayhty","year":"1983","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.010","article-title":"Inherited complement deficiencies and bacterial infections","author":"Tedesco","year":"2008","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.06.008","article-title":"Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation","volume":"144","author":"J\u00f6nsson","year":"2012","journal-title":"Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.1.163","article-title":"Bactericidal and opsonic activity of IgGl and IgG2 anticapsular antibodies to haemophilus influenzae type b","volume":"162","author":"Amir","year":"1990","journal-title":"J Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/iai.44.2.452-458.1984","article-title":"Antibody-dependent alternative pathway killing of haemophilus influenzae type b","volume":"44","author":"Steele","year":"1984","journal-title":"Infect Immun"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.128.4.1772","article-title":"The requirement of specific anticapsular IgG for killing of haemophilus influenzae by the alternative pathway of complement activation","volume":"128","author":"Tarr","year":"1982","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/iai.48.1.183-189.1985","article-title":"Serum opsonic activity after immunization of adults with haemophilus influenzae type b-diphtheria toxoid conjugate vaccine","volume":"48","author":"Cates","year":"1985","journal-title":"Infect Immun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2016.168","article-title":"Liver-guardian, modifier and target of sepsis","volume":"14","author":"Strnad","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0882-4010(89)90012-0","article-title":"Roles of spleen and liver in the clearance of escherichia coli K1 bacteraemia in infant rats","volume":"6","author":"Pelkonen","year":"1989","journal-title":"Microb Pathog"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.7189\/jogh.12.04014","article-title":"Estimating the global and regional burden of meningitis in children caused by haemophilus influenzae type b: A systematic review and meta-analysis","volume":"12","author":"Park","year":"2022","journal-title":"J Glob Health"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12154","article-title":"Complement profile in neonates of different gestational ages","volume":"79","author":"Grumach","year":"2014","journal-title":"Scand J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1987.tb17268.x","article-title":"Concentrations of C1q, factor b, factor d and properdin in healthy children, and the age-related presence of circulating C1r-C1s complexes","volume":"76","author":"Prellner","year":"1987","journal-title":"Acta Paediatr Scand"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1999.tb00988.x","article-title":"Complement haemolytic activity (classical and alternative pathways), C3, C4 and factor b titres in healthy children","volume":"88","author":"Ferriani","year":"1999","journal-title":"Acta Paediatr Int J Paediatr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00100-15","article-title":"Seroprevalence of antibody-mediated, complement-dependent opsonophagocytic activity against neisseria meningitidis serogroup b in England","volume":"22","author":"Humphries","year":"2015","journal-title":"Clin Vaccine Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1020580\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T08:59:27Z","timestamp":1679043567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1020580\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2022.1020580"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1020580","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"article-number":"1020580"}}